The content on this site is intended for healthcare professionals only
Results from CABOSUN, METEOR and JAVELIN trials in kidney cancer
Breast cancer highlights from ESMO 2018
Comment on 'Ovarian Cancer: An ESMO Guide for Patients'
The IMpower-132 trial for non small cell lung cancer
ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD 1 refractory melanoma
Keynote lecture: Mutation signatures and targeting the DNA damage response
Dosing regiment in the combination of ipilimumab and nivolumab in stage III melanoma
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma
Modern melanoma treatment in the UK
Current clinical landscape for ALK non-small cell lung cancer patients
Latest advances in treatment for ALK positive NSCLC
The case for biosimilars
Highlights in early non-metastatic NSCLC and thoracic tumours
Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC
Combination strategies of immunotherapy in breast cancer
Highlights in SCLC from ESMO 2018
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC
Safety analysis of entrectinib for NTRK fusion tumours
TRITON2: Evaluation of rucaparib in patients with metastatic castration-resistant prostate cancer
ASCEND-8: safety data of ceritinib with or without food in NSCLC
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer
Lung highlights from ESMO 2018
Erlotinib for neoadjuvant treatment of EGFR NSCLC
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC
20 year followup on high-dose chemo with HSCT in high-risk breast cancer
Opportunities for biosimilars in practice and education
Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer
VALENTINO: Maintenance therapy in advanced CRC
Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA
The Circulating Cell-Free Genome Atlas Study
The standard of care and progress so far with PARP inhibitors for ovarian cancer
Cardiac events in stage III NSCLC treated in daily clinical practice
Ceritinib and ribociclib in ALK-positive NSCLC
Cemiplimab in patients with hepatocellular carcinoma
Updates from the EMBRACA trial for advanced breast cancer
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy
Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer
Liquid biopsy as a monitoring tool for the benefit of chemotherapy-immunotherapy in aNSCLC
Comment on the Every Woman Study
Therapeutic targeting at a pre-metastatic stage for brain metastases from lung cancer
Recent advances in CNS tumour management
Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer
Updates in head and neck cancers
KEYNOTE022: Triplet therapy for BRAF melanoma
First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
SPLENDOUR: Added denosumab in first line adv NSCLC treatment
Women 4 Oncology: Advancing the careers of female oncologists
Cisplatin superior to cetuximab for HPV oropharyngeal cancer
Cisplatin v cetuximab for HPV associated oropharyngeal cancer
Assessing radiotherapy for men with newly diagnosed metastatic prostate cancer
ESMO 2018: Melanoma highlights
IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy
KEYNOTE048: First line pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma
ESMO 2018: Highlights
IMpassion 130 trial results: Immunotherapy for metastatic breast cancer
The TRIBE-2 study for colorectal cancer
Advances in metastatic non small cell lung cancer
Detecting copy number alterations using a pre-natal test
Comment on the JAVELIN study: RCC immunotherapy
Use of T-VEC in early metastatic melanoma
KEYNOTE 10: Pembrolizumab vs docetaxel for NSCLC
PEACE: Collecting cancer tissue to solve the riddle of metastasis
Expansion from CHECKMATE-032; nivolumab and ipilimumab for metastatic urothelial carcinoma
Comment: Radiotherapy as a treatment option for metastatic prostate cancer
JAVELIN Renal 101 trial: avelumab and axitinib for advanced renal cell carcinoma
Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
Survival results from STAMPEDE, radiotherapy for prostate cancer
The past, present and future of treating ovarian cancer
Comment on SOLO-1 for advanced ovarian cancer
Olaparib improves progression free survival up front in ovarian cancer
Comment on SOLO1 trial
A novel bifunctional fusion protein for combatting lung cancer
Comment on new treatment options for breast cancer
Early stage trials in immunotherapy and brain screening
Results from the PALOMA-3 trial for advanced breast cancer
PALOMA-3 update, including OS data for HR positive HER2 negative breast cancer
Results from the SOLAR-1 trial for advanced breast cancer
Economics and education around biosimilars
Results from the IMpassion130 trial for triple-negative breast cancer
Alpelisib and fulvestrant for advanced breast cancer: SOLAR-1
Magnetic marker to judge pathological response to checkpoint therapy in melanoma
Rare EGFR mutations in lung adenocarcinoma
Societal indicators of lung cancer screening behaviours
New therapeutic options in advanced and metastatic breast cancer
